|Description||GW 627368X is a potent and selective competitive antagonist of the EP4 receptor with additional human TP receptor affinity (Ki values of 100 nM and 158 nM, respectively).|
|B0084-313850||50 mg||$188||In stock|
|Appearance||A crystalline solid|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||A potent and selective competitive antagonist.|
|Quality Standard||Enterprise Standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly|
FR-181157 is an orally active prostacyclin mimetic that shows high potency and agonist efficacy at the IP receptor.
Ethamsylate is a haemostatic drug, which inhibits biosynthesis and action of prostaglandins, and increases capillary endothelial resistance as and platelet adhe...
E7046 is an orally bioavailable and specific type 4 prostaglandin E2 (PGE2) receptor EP antagonist (IC50= 13.5 nM) (Ki= 23.14 nM), with anti-tumor activities.
Terutroban is a potent, orally active antagonist of the thromboxane/prostaglandin A2(TP) receptor (IC50 = 16.4 nM). In guinea pigs it also inhibits U 46619 indu...
GSK-345931A is an EP(1) receptor antagonist. It is efficient in preclinical models of inflammatory pain.
MF592 is a potent and selective antagonists of the EP4 receptor. It has good functional potency and potent inhibition of PGE2 modulated TNFa release in LPS stim...
GW 627368X is a potent and selective competitive antagonist of the EP4 receptor with additional human TP receptor affinity (Ki values of 100 nM and 158 nM, resp...
Grapiprant, also known as CJ-023,423, RQ-00000007 and AAT-007, is a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic prop...
(+)-Cloprostenol sodium salt
(+)-Cloprostenol sodium salt is the d-enantiomer of Cloprostenol, which is an aryl-oxymethyl analog of prostaglandin F2α. It has luteolytic effects and is used ...
CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist. It inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5. It ...
This active molecular is a potent Prostaglandin D2 receptor antagonists and has been in phase I clinical trials for both COPD (chronic obstructive pulmonary dis...
CP-533536, also called as Evatanepag, a 3-pyridyl sulfonamide compound, demonstrated excellent in vitro potency against prostaglandin E2 (PGE2) (induces local b...
A EP1 antagonist (pKi= 7.54) (pIC50= 8.5)
Ifetroban is a selective Prostaglandin receptor and Thromboxane A2 receptor antagonist under the development of Bristol-Myers Squibb. Phase II clinical trials f...
PF-04418948 is a potent and selective prostaglandin EP₂ receptor antagonist with IC50 of 16 nM. Phase 1. PF-04418948 antagonizes the effects of butaprost and PG...
ONO-AE3-208 is an EP4 antagonist (Ki values are 1.3, 30, 790 and 2400 nM for EP4, EP3, FP and TP receptors respectively), which less potently affects EP3, FP, a...
Mf-63 is a selective Microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Its IC50 value is 0.9 nM and 1.3 nM for pig mPGES-1 and human mPGES-1 enzyme, r...
Cloprostenol sodium is a synthetic and water-soluble aryl-oxymethyl analog of prostaglandin F2α. lt is also a potent inhibitor of rat adipose precursor differen...
PF-04217329 is a potent and selective EP2 receptor agonist on intraocular pressure in preclinical models of glaucoma. It is a prodrug of CP-544326. It is well t...
MF498 is a novel and selective E prostanoid receptor 4 (EP4 receptor) antagonist, a Gs protein-coupled receptor, with Ki of 0.7 nM. It plays important roles in ...